Soluble cytokine receptors (sIL-2Rα, sIL-2Rβ) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Zalcman, Steven S ^a   Patel, Ankur ^a   Mohla, Ruchika ^a   Zhu, Youhua ^a   Siegel, Allan ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C FOS; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR ALPHA; SOLUBLE INTERLEUKIN 2 RECEPTOR BETA; UNCLASSIFIED DRUG; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; FOREBRAIN; IMMUNOREACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PUTAMEN; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; NEOSTRIATUM; SOLUBILITY;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; NEOSTRIATUM; PROTO-ONCOGENE PROTEINS C-FOS; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 84860460480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036316     Document Type: Article

References (24)

1. Rose-John S, Heinrich PC, (1994) Soluble receptors for cytokines and growth factors: generation and biological function. The Biochemical Journal 300: 281-290.
2. Novick D, Rubinstein M, (2007) The tale of soluble receptors and binding proteins: from bench to bedside. Cytokine Growth Factor Reviews 18: 525-533.
3. Levin SJ, (2008) Molecular mechanisms of soluble cytokine receptor generation. Journal of Biological Chemistry 283: 77-81.
4. Fulop T, Larbi A, Douziech N, Levesque I, (2006) Cytokine receptor signalling and aging. Mechanisms of Ageing and Development 127: 526-537.
5. Hanisch UK, Quirion R, (1995) Interleukin-2 as a neuroregulatory cytokine. Brain Research Reviews 21: 246-284.
6. Honda M, Kitamura K, Takeshita T, Sugamura K, Tokunaga T, (1990) Identification of a soluble IL-2 receptor beta-chain from human lymphoid cell line cells. Journal of Immunology 145: 4131-4135.
7. Suh CH, Kim HA, (2008) Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Review of Molecular Diagnostics 8: 189-198.
8. Bien E, Balcerska A, (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 13: 1-26.
9. Caruso C, Candore G, Cigna D, Colucci AT, Modica MA, (1993) Biological significance of soluble IL-2 receptor. Mediators of Inflammation 2: 3-21.
10. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH, (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. American Journal of Psychiatry 150: 1408-1410.
11. Rapaport MH, Caligiuri MP, Lohr JB, (1997) An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients. Progress in neuro-psychopharmacology & biological psychiatry 21: 817-827.
12. Kowalski J, Blada P, Kucia K, Lawniczek T, Madej A, et al. (2000) In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia. The World Journal of Biological Psychiatry 1: 190-196.
13. Ebrinç S, Top C, Oncül O, Başoǧlu C, Cavuşlu S, et al. (2002) Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. The Journal of international medical research 30: 314-317.
14. Bresee C, Rapaport MH, (2009) Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. International Journal of Neuropsychopharmacology 12: 861-865.
15. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, et al. (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 63: 801-808.
16. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, et al. (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophrenia Research 25: 123-129.
17. Rapaport MH, Lohr JB, (1994) Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta psychiatrica Scandinavica 90: 311-315.
18. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY, (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 29: 141-152.
19. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ, (2001) Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. Journal of Affective Disorders 64: 185-193.
20. Zalcman SS, (2001) Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. Brain Research 899: 1-9.
21. Zalcman SS, (2002) Interleukin-2-induced increases in climbing behavior: inhibition by dopamine D-1 and D-2 receptor antagonists. Brain Research 19; 944: 157-164.
22. Ellery JM, Nicholls PJ, (2002) Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction. Immunology and Cell Biology 80: 351-317.
23. Bien E, Balcerska A, (2008) Serum soluble interleukin-2 receptor alpha in human cancer of adults and children: a review. Biomarkers 13: 1-26.
24. Taylor JM, Pollard JD, (2007) Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. Journal of Neuroimmunology 183: 118-124.